[1] Fernandez M. Placental growth factor: new treatment Target bringing hope in hepatopulmonary syndrome. Hepatology, 2018, doi: 10.1002/hep.29795.
[2] Raevens S, Geerts A, Paridaens A, et al. Placental growth factor inhibition targets pulmonary angiogenesis and represents a novel therapy for hepatopulmonary syndrome in mice. Hepatology, 2017, doi: 10.1002/hep.29579.
[3] Van Steenkiste C, Ribera J, Geerts A, et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology, 2011, 53:1629-1640.
[4] Zhang J, Fallon MB. Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol, 2012, 9: 539-549.
[5] Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med, 2003, 9:936-943. |
